{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Time to subsequent treatment (TTS) was defined as time from end of active (protocol) treatment to the start of subsequent treatment for participants with progressive disease. The median TTS with 95% CI was estimated using the Kaplan Meier method","dispersionType":"95% Confidence Interval","groups":[{"description":"Thalidomide (Thal) + Zolendronic acid (ZLD)","id":"OG000","title":"Arm I: Thal/ZLD"},{"description":"Zoledronic acid (ZLD)","id":"OG001","title":"Arm II: ZLD"}],"paramType":"MEDIAN","populationDescription":"This data was not (and will never be) analyzed as it was not submitted consistently across all participants.","reportingStatus":"POSTED","timeFrame":"time from end of treatment to subsequent treatment (up to 5 years)","title":"Time to Subsequent Treatment","type":"SECONDARY","unitOfMeasure":"years"}